Leap Therapeutics, Inc. (LPTX) Wednesday reported positive preliminary data from DeFianCe Phase 2 study of sirexatamab, the company's most advanced drug candidate, in colorectal cancer.
The part B of the DeFianCe study evaluated sirexatamab in combination with bevacizumab and chemotherapy compared to bevacizumab and chemotherapy in patients with advanced microsatellite stable (MSS) colorectal cancer (CRC). Results from the study showed that patients treated with sirexatamab plus bevacizumab and chemotherapy have a statistically significant 32 percent higher overall response rate (ORR), 3.5 month longer progression-free survival (PFS), and overall survival (OS) compared to those who were on bevacizumab and chemotherapy.
Additionally, patients who had not received prior anti-VEGF therapy, treated with sirexatamab combo have a statistically significant 22 percent higher ORR and 2.6 month longer PFS.
For comments and feedback: editorial@rttnews.com